Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Recruiting · NCT05786040 · Registry updated 2026-04-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder; Polymorphic Post-Transplant Lymphoproliferative Disorder | Recruiting | Phase 2 | 2026-04-14 | NCT05786040 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Timothy Voorhees | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Huntsman Cancer Institute | Salt Lake City | United States | 107 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | United States | 223 |
| University of North Carolina-Hillsborough Campus | Hillsborough | United States | 18 |